Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purcha...
Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...
Introduction A lot has happened at ChemoCentryx (NASDAQ: CCXI ) since my first report back in November 2017. Following the release of the ADVOCATE trial top-line results in late November 2019, ChemoCentryx share price more than quadrupled and interest in the company spiked. Analysts ...
MOUNTAIN VIEW, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part of the virtual annual meetings of the leading European rheumatology and nephrology organiz...
Rational for a Copycat Strategy Research from Barclay and Novus published in October 2019 found that a stock selection copycat strategy that combines conviction and consensus of fund managers that have longer-term views outperformed the S&P 500 by 3.80% on average annually from Q1 2004...
Deciphera Receives FDA Approval for GIST Therapy Deciphera Pharmaceuticals ( DCPH ) reported that it has received an early FDA approval for Qinlock for treating patients with gastrointestinal stromal tumor (GIST). The treatment is specifically targeted at patients who did not response to...
ChemoCentryx (NASDAQ: CCXI ) and collaboration partner Vifor Fresenius Medical Care Renal Pharma announce "disappointing" topline data from a Phase 2 clinical trial, LUMINA-1 , evaluating CCX140 in patients with primary focal segmental glomerulosclerosis (FSGS), a condition in which sca...
MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary F...
ChemoCentryx, Inc. (CCXI) Q1 2020 Results Conference Call May 11, 2020 05:00 PM ET Company Participants Bill Slattery - IR, Burns McClellan Dr. Thomas Schall - President and CEO Susan Kanaya - EVP, Chief Financial and Administrative Officer Conference Call Participants Stev...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2020 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...